BPC-157 + TB-500 (The Wolverine Stack)

BPC-157 and TB-500 are the most widely discussed peptide combination in the recovery and biohacking community. Known as the "Wolverine Stack" for its association with accelerated healing, this combination is the go-to recovery protocol discussed by practitioners and athletes. The rationale is complementary mechanisms: BPC-157 appears to promote localized tissue repair through angiogenesis and growth factor modulation, while TB-500 (a fragment of thymosin beta-4) supports systemic healing through cell migration, anti-inflammatory signaling, and actin regulation. Practitioners who discuss this combination suggest that BPC-157 works best at or near the injury site, while TB-500 provides a broader systemic repair signal. The idea is that combining localized and systemic approaches may produce more complete recovery than either compound alone.

BPC-157 upregulates VEGF, EGF, and FGF expression, promoting angiogenesis and tissue granulation at injury sites. It modulates the nitric oxide system and has demonstrated cytoprotective effects on gastric mucosa. TB-500 acts through a different pathway — it sequesters G-actin monomers, promoting cell migration and reducing inflammation via downregulation of NF-kB. TB-500 also promotes angiogenesis but through thymosin beta-4's interaction with actin dynamics rather than growth factor upregulation. The proposed synergy is mechanistic complementarity: BPC-157 drives local vascularization and growth factor signaling while TB-500 facilitates the cellular migration needed to populate the newly vascularized tissue. Both have independent anti-inflammatory properties through distinct pathways.

There are no published studies on BPC-157 and TB-500 used in combination. The evidence for each compound individually is predominantly preclinical. BPC-157 has hundreds of animal studies showing tissue repair effects but very limited human data — a 2025 systematic review in orthopaedic sports medicine confirmed the preclinical promise while noting the absence of human RCTs. TB-500's parent compound thymosin beta-4 has more clinical development history, including studies in wound healing and dry eye, but TB-500 itself (the active fragment) has limited human trial data. The combination rationale is based on mechanistic reasoning and practitioner observation, not clinical trial evidence for the stack specifically. This is an important distinction: the individual compounds have reasonable preclinical support, but the synergy claim is theoretical.

Protocols discussed in clinical settings typically involve subcutaneous injection of both peptides, often administered at or near the site of injury for BPC-157 and systemically for TB-500. Specific dosing and duration should be determined by a qualified clinician. Both peptides are typically used in time-limited cycles rather than indefinitely. The combination is most commonly discussed for acute injury recovery and post-surgical healing support.